Web Analytics
Cổ phiếu BMY (NYSE) | BRISTOL-MYERS SQUIBB COMPANY – Phân tích Deepscope
MARKET

Select Market Data Region

BMY — BRISTOL-MYERS SQUIBB COMPANY (Healthcare >> Drug Manufacturers - General)

BMY FAQ

What is BMY's P/E ratio?

BRISTOL-MYERS SQUIBB COMPANY (BMY) currently trades at a P/E ratio of 15.36.

What is BMY's ROE?

BRISTOL-MYERS SQUIBB COMPANY reports a Return on Equity (ROE) of 36.25%.

What is BMY's dividend yield?

BRISTOL-MYERS SQUIBB COMPANY offers a dividend yield of 4.59%.

What is BMY's Deepscope Quality Score?

Deepscope rates BMY's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BMY?

Deepscope's AI Timing Score for BMY is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BMY belong to?

BRISTOL-MYERS SQUIBB COMPANY is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-03 | FS: 2026-03-31)

BMY

BRISTOL-MYERS SQUIBB COMPANY
USD 54.72
0.26 (0.48%) Day Change
15.36
P/E
2.22
D/E
36.3%
ROE
8.4%
ROA
4.59%
Div Yield
-0.13
PEG

BRISTOL-MYERS SQUIBB COMPANY
TYPE: STOCK
MARKET: NYSE

Compare   Watchlist   Myport
USD 54.72
Price
0.26 (0.48%)
Day Change
NEWS SCORE: 89

BMY Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 62) và Thời điểm mua ...(Sign In to See)...

62

QUALITY

Signal
NEUTRAL
Signal Description
Company financial health is OK
Reason
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng 48%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 89
  Magic Formula Rank by ROA
828
  Magic Formula Rank by ROE
828
  Magic Formula Rank by ROIC
836
  Price 54.72
  PBV / Sector
5.56 / 2.77
  Earning Per Share 3.56
  PE / Sector
15.36 / 23.60
  PEG or PE/Growth / Sector
-0.13 / 0.07
  Average 1M Daily Value
511.37 M
  Average 1W Daily Value
659.31 M
Yếu tố Kỹ thuật 14%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Sức khỏe tài chính 47%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Khả năng kiếm lợi nhuận 70%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
15.01 / 18.17
GOOD
  NPM Average (%) / Sector
8.53 / 17.77
  NPM Change Average (%) / Sector
-87.57 / 93.90
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
8.41 / 8.90
  ROA Average (%) / Sector
4.31 / 8.60
  ROA Change Average (%) / Sector
-89.80 / 95.12
  ROE (%) / Sector
36.25 / 27.16
GREAT
  ROE Average (%) / Sector
13.46 / 13.13
  ROE Change Average (%) / Sector
-110.44 / 97.95
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Lợi tức cho nhà đầu tư 83%
X
  Dividend (%) / Sector
4.59 / 2.59
GOOD
  Dividend Average (%) / Sector
4.44 / 3.43
GOOD
  Dividend Change Average (%) / Sector
8.93 / 2.04
Chi tiết đăng ký
X
  Analyze Date 2026-06-04 09:24:06
  Symbol BMY
  Name BRISTOL-MYERS SQUIBB COMPANY
  Sector Healthcare >> Drug Manufacturers - General
  Market NYSE
  Listed Shares 2,042.07 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 111,742.14 / 232,396.15
Tin tức, Dự báo ước tính
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Phone: 609 252 4621

Website: https://www.bms.com

Employees: 32,500

Sector: Healthcare >> Drug Manufacturers - General

Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

ME vs SECTOR Healthcare >> Drug Manufacturers - General

BMY (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
BMY
BMY
USD 54.72 (0.48%)
+ Watch + Port Chart